UK-based drug development company Avillion LLP has appointed Allison Jeynes-Ellis as chief executive.
Dr Jeynes-Ellis (pictured) has more than 20 years of senior leadership experience in the pharmaceutical industry. She has managed both large and small teams focusing on global clinical development projects that have led to new drug approvals in Europe and the USA, across a range of therapeutic areas. Dr Jeynes-Ellis is a founding member of Avillion’s management team and was formerly the company’s Chief Medical Officer.
During her career, Dr Jeynes-Ellis has worked in senior roles in pharmaceutical companies, including Wyeth, Bristol-Myers Squibb, and Novartis; and as an independent consultant to many companies, including CAT and Genentech, government bodies and medical research charities. She was previously Medical Director at Wyeth (UK and Ireland), where she led a large team spanning various clinical development, regulatory affairs and commercial functions. Dr Jeynes-Ellis was also Medical & Innovation Director at the Association of British Pharmaceutical Industry (ABPI). She is a currently a non-executive director of the Health Research Authority and BioCity, Scotland.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze